![Hummingbird Bioscience on Twitter: "#HummingbirdBioscience announces first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3 expressing solid malignancies. The trial Hummingbird Bioscience on Twitter: "#HummingbirdBioscience announces first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3 expressing solid malignancies. The trial](https://pbs.twimg.com/media/FF6j227VgAMRALA.jpg:large)
Hummingbird Bioscience on Twitter: "#HummingbirdBioscience announces first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3 expressing solid malignancies. The trial
![SITC 2021: A Phase 1 First-in-Human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies | Hummingbird Bioscience SITC 2021: A Phase 1 First-in-Human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies | Hummingbird Bioscience](https://hummingbirdbioscience.com/wp-content/uploads/2022/11/A-Phase-1-First-in-Human-Study-of-HMBD-002-an-IgG4-Monoclonal-Antibody-Targeting-VISTA-scaled.jpg)
SITC 2021: A Phase 1 First-in-Human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies | Hummingbird Bioscience
![HMBD-002 is a unique anti-VISTA antibody, immunoengineered to bind to a... | Download Scientific Diagram HMBD-002 is a unique anti-VISTA antibody, immunoengineered to bind to a... | Download Scientific Diagram](https://www.researchgate.net/publication/358437403/figure/fig1/AS:1121708148826117@1644447471061/HMBD-002-is-a-unique-anti-VISTA-antibody-immunoengineered-to-bind-to-a-rationally_Q320.jpg)